Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Kuczynski, Christina Lee, S. Man, E. Chen, R. Kerbel (2015)Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma.
Cancer research, 75 12
O. Abdel-Rahman, A. Lamarca (2017)Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival
Expert Review of Gastroenterology & Hepatology, 11
J. Autier, B. Escudier, J. Wechsler, A. Spatz, C. Robert (2008)Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Archives of dermatology, 144 7
C. Robert, V. Sibaud, C. Mateus, B. Cherpelis (2012)Advances in the management of cutaneous toxicities of targeted therapies.
Seminars in oncology, 39 2
Hiroaki Shichiri, Kazuhiro Yamamoto, Maya Tokura, T. Ishida, A. Uda, T. Bito, C. Nishigori, Tsutomu Nakagawa, Takeshi Hirano, I. Yano, M. Hirai (2017)Prostaglandin E1 reduces the keratinocyte toxicity of sorafenib by maintaining signal transducer and activator of transcription 3 (STAT3) activity and enhancing the cAMP response element binding protein (CREB) activity.
Biochemical and biophysical research communications, 485 2
R. Gutzmer, A. Wollenberg, S. Ugurel, B. Homey, A. Ganser, A. Kapp (2012)Cutaneous side effects of new antitumor drugs: clinical features and management.
Deutsches Arzteblatt international, 109 8
M. Lacouture, Shenhong Wu, C. Robert, M. Atkins, H. Kong, J. Guitart, C. Garbe, A. Hauschild, I. Puzanov, D. Alexandrescu, Roger Anderson, L. Wood, J. Dutcher (2008)Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
The oncologist, 13 9
M. Ikeda, T. Fujita, Sumiyuki Mii, K. Tanabe, K. Tabata, Kazumasa Matsumoto, T. Satoh, M. Iwamura (2012)Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.
Japanese journal of clinical oncology, 42 9
A. Kontzias, A. Laurence, M. Gadina, J. O’Shea (2012)Kinase inhibitors in the treatment of immune-mediated disease
F1000 Medicine Reports, 4
C. Yang, W-C. Lin, Chen Chuang, Y‐C. Chang, S. Pang, Y‐C. Lin, TT Kuo, J. Hsieh, J.W-C. Chang (2007)Hand‐foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy
British Journal of Dermatology, 158
S. Lai, T. Kuzel, M. Lacouture (2007)Hand-foot and stump syndrome to sorafenib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 3
R Gutzmer, A Wollenberg, S Ugurel, B Homey, A Ganser, A Kapp (2012)Cutaneous side effects of new antitumor drugs: clinical features and management
Dtsch Arztebl Int, 109
R. Gilbert, M. Vickaryous, A. Viloria‐Petit (2016)Signalling by Transforming Growth Factor Beta Isoforms in Wound Healing and Tissue Regeneration
Journal of Developmental Biology, 4
R. Sparidans, M. Vlaming, J. Lagas, A. Schinkel, J. Schellens, J. Beijnen (2009)Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 877 3
Kazuhiro Yamamoto, Atsushi Mizumoto, K. Nishimura, A. Uda, Akira Mukai, Kazuhiko Yamashita, M. Kume, H. Makimoto, T. Bito, C. Nishigori, Tsutomu Nakagawa, Takeshi Hirano, M. Hirai (2014)Association of Toxicity of Sorafenib and Sunitinib for Human Keratinocytes with Inhibition of Signal Transduction and Activator of Transcription 3 (STAT3)
PLoS ONE, 9
K. Chanprapaph, S. Rutnin, V. Vachiramon (2016)Multikinase Inhibitor-Induced Hand–Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management
American Journal of Clinical Dermatology, 17
A. Lipworth, C. Robert, A. Zhu (2009)Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib
J. Ulrich, J. Hartmann, W. Dörr, S. Ugurel (2008)Skin toxicity of anti‐cancer therapy
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 6
J Ulrich, JT Hartmann, W Dorr, S Ugurel (2008)Skin toxicity of anti-cancer therapy
J Dtsch Dermatol Ges, 6
Jian-xin Xia, Xiang Mei, Wenjing Zhu, Xue Li, Xianhua Jin, Y. Mou, Kai Yu, Yi-yu Wang, Fuqiu Li (2014)Effect of FGF10 monoclonal antibody on psoriasis-like model in guinea pigs.
International journal of clinical and experimental pathology, 7 5
P. Massey, Jonathan Okman, J. Wilkerson, E. Cowen (2015)Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature
Supportive Care in Cancer, 23
M Ikeda, T Fujita, S Mii, K Tanabe, K Tabata, K Matsumoto, T Satoh, M Iwamura (2012)Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma
Jpn J Clin Oncol, 42
G. Dy, A. Adjei (2013)Understanding, recognizing, and managing toxicities of targeted anticancer therapies
CA: A Cancer Journal for Clinicians, 63
B. Baker, L. Brent, H. Valdimarsson, A. Powles, L. Al-Imara, M. Walker, L. Fry (1992)Is epidermal cell proliferation in psoriatic skin grafts on nude mice driven by T‐cell derived cytokines?
British Journal of Dermatology, 126
H. Yasui, K. Imai (2008)Novel molecular-targeted therapeutics for the treatment of cancer.
Anti-cancer agents in medicinal chemistry, 8 5
Objectives To investigate the pathologic changes and pathogenesis of multikinase inhibitor (MKI)-induced skin lesions in an animal model. Methods Tumor-bearing nude mice and BDF1 mice were treated with different doses (30–240 mg/kg, Bid) of sorafenib. The pathology and severity of the skin lesions was assessed and evaluated. The concentration of sorafenib in the skin was also determined. Results Sorafenib transiently induced skin rash at high doses (120–240 mg/kg). The induced skin lesions had pathological manifestations resembling the observations in human patients. The skin of mice treated with sorafenib had significantly increased pathological scores and thickness of the stratum spinosum compared with the control, and induced more severe cutaneous lesions in nude mice than in BDF1 mice. The severity of skin lesions was correlated with the local concentration of sorafenib in the skin, which was significantly higher in nude mice than in BDF1 mice. Sorafenib treatment significantly increased the expression of F4-80, Ly6G, tumor growth factor (TGF)-1β, Smad2/3, α-smooth-muscle actin, and proliferat- ing cell nuclear antigen. Conclusions The severity of skin lesions was positively correlated with the concentration of sorafenib in the skin. Our results suggested the involvement of the TGF-β1/Smads signaling pathway in the skin reaction induced by MKIs. Keywords Multikinase
Cancer Chemotherapy and Pharmacology – Springer Journals
Published: Apr 9, 2018
Access the full text.
Sign up today, get DeepDyve free for 14 days.